Please try another search
For the six months ended 30 June 2016, Medgenics, Inc. revenues was not reported. Net loss increased 52% to $22.9M. Higher net loss reflects Other General & Administration expense increase of 46% to $4.4M (expense), Financial income decrease of 92% to $2K (income). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.60 to -$0.69.
Period Ending: | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -11.69 | -11.14 | -6.44 | -15.37 |
Net Income | -11.71 | -11.14 | -6.46 | -16.52 |
Period Ending: | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 |
---|---|---|---|---|
Total Assets | 55.3 | 45.16 | 54.26 | 19.59 |
Total Liabilities | 3.93 | 3.56 | 3.91 | 10.41 |
Total Equity | 51.38 | 41.61 | 50.35 | 9.18 |
Period Ending: | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 |
---|---|---|---|---|
Period Length: | 6 Months | 3 Months | 12 Months | 9 Months |
Cash From Operating Activities | -18.94 | -9.11 | -24.35 | -16.88 |
Cash From Investing Activities | -0.19 | -0.06 | -0.19 | -0.11 |
Cash From Financing Activities | 19.75 | 0 | 44.31 | 1.43 |
Net Change in Cash | 0.62 | -9.17 | 19.78 | -15.56 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review